Actively Recruiting
Study of Neurocognitive and Psychiatric Effects of Targeted Therapies for Lung Cancer With ALKROS1 Fusion and Their Impact on Quality of Life Building a Collaborative Care and Research Pathway with Patient Involvement
Led by Hospices Civils de Lyon · Updated on 2025-12-30
20
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying neurocognitive and psychiatric disorders linked to targeted cancer therapies used for metastatic lung cancer with ALKROS1 fusion. These therapies, which inhibit specific proteins, have improved survival but may cause cognitive and mood problems more severe than those seen with chemotherapy. The study aims to describe these disorders through detailed assessments and understand their impact on patients quality of life using a collaborative approach involving patients, researchers, and clinicians. Participants who have ALKROS1-positive lung cancer treated with anti-ITK-ALKROS1 therapies and report cognitive or psychiatric complaints undergo thorough evaluations. These assessments take place over one or two days, including neuropsychiatric and neurocognitive testing by specialists, and psychosocial evaluations either in person or remotely using questionnaires about daily life and social relationships. Data collected will be analyzed both qualitatively and quantitatively to capture the full patient experience. During the study, participants will have detailed visits involving psychiatrists, neuropsychologists, neurologists, and social psychologists. Assessments include clinical evaluations, standardized quality of life questionnaires, and interviews to explore the effects of treatment-related complaints on daily living. The main outcome is the characterization of neurocognitive and neuropsychiatric symptoms linked to the targeted therapies. Participation continues from enrollment through the completion of these evaluations, helping to better understand and support affected patients.
CONDITIONS
Brief Title
Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway
Research Team
M
Michael DURUISSEAUX, Professor
V
Virginie DESESTRET, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
